Plural Chalcogens Bonded Directly To Ring Carbons Of The Piperidine Ring Patents (Class 514/328)
  • Patent number: 9598390
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Hao Zhang, Peter T. W. Cheng, Shiwei Tao
  • Patent number: 9580420
    Abstract: A process is provided for preparing 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates used in the process. The compound is a 11-beta hydroxysteroid dehydrogenase type I inhibitor which exhibits activity in the treatment of various metabolic diseases.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: February 28, 2017
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Xinhua Qian, Keming Zhu, Joerg Deerberg, Wendy Wangying Yang, Kana Yamamoto, Matthew R. Hickey
  • Patent number: 9518000
    Abstract: The present invention provides compounds of Formula (I): (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 13, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter T. W. Cheng, Ying Wang, Shung C. Wu, Hao Zhang
  • Publication number: 20150119366
    Abstract: Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 30, 2015
    Inventors: Yanming Du, Xiaodong Xu, Hong Ye, Jinhong Chang, Timothy M. Block
  • Patent number: 9000011
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 7, 2015
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David Lockhart, Jeff Castelli
  • Patent number: 8957062
    Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 17, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott Edmondson, Zhiqiang Guo, Harold B. Wood, Andrew W. Stamford, Michael W. Miller, Duane E. DeMong, Gregori J. Morriello, Rajan Anand, Vincent J. Colandrea, Megan Macala, Milana Maletic, Cheng Zhu, Yuping Zhu, Wanying Sun, Kake Zhao, Yong Huang, Joel M. Harris, Lehua Chang, Nam Fung Kar, Zhiyong Hu, Liping Wang, Bowei Wang, Ping Liu, Jason W. Szewczyk, William B. Geiss
  • Publication number: 20150031670
    Abstract: Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: March 21, 2013
    Publication date: January 29, 2015
    Applicant: MERCK PATENT GmbH
    Inventors: Timo Heinrich, Frank Zenke, Mireille Krier, Manja Friese-Hamim, Jeyaprakashnarayanan Seenisamy
  • Publication number: 20150031656
    Abstract: The present invention relates to a combination therapy for elevating testosterone levels in male mammals in which an antiestrogen or pharmaceutically acceptable salt thereof is co-administered to the mammal with an additional therapeutic agent selected from an androgen and an aromatase inhibitor. The invention is also directed to a combination therapy for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 29, 2015
    Inventors: Joseph S. Podolski, Ronald D. Wiehle
  • Patent number: 8802871
    Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Branko Mitasev, Dae-Shik Kim, Huiming Zhang, Matthew J. Schnaderbeck, Christopher N. Farthing
  • Patent number: 8772493
    Abstract: The present invention relates to a compound represented by formula 1 in the present specification or a pharmaceutically acceptable thereof, which inhibits an apoptosis mechanism of auditory hair cells for various ototoxicities leading to deafness, and protects the auditory organ and hearing, a method for preparation thereof, and a composition containing the same.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: July 8, 2014
    Assignees: Ajou University Industry-Academic Cooperation Foundation, Korea Research Institute of Chemical Technology
    Inventors: Chul Ho Kim, Young Sik Jung
  • Patent number: 8748460
    Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 10, 2014
    Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20140086896
    Abstract: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 27, 2014
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Publication number: 20140080871
    Abstract: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Patent number: 8673935
    Abstract: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: March 18, 2014
    Assignees: Genethon, Centre National de la Recherche Scientifique
    Inventor: Isabelle Richard
  • Publication number: 20140057844
    Abstract: The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies.
    Type: Application
    Filed: December 2, 2011
    Publication date: February 27, 2014
    Inventors: Tin Tin Su, Gan Zhang
  • Patent number: 8642622
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: February 4, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert J. Cherney, John V. Duncia, Daniel S. Gardner, Joseph B. Santella, Zhongyu Wang
  • Publication number: 20140024639
    Abstract: Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.
    Type: Application
    Filed: July 19, 2013
    Publication date: January 23, 2014
    Inventors: Drew Adams, Mingji Dai, Stuart Schreiber, Mahmud Mustaqim Hussain, Zarko Boskovic
  • Patent number: 8604206
    Abstract: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: December 10, 2013
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Publication number: 20130315981
    Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.
    Type: Application
    Filed: June 22, 2011
    Publication date: November 28, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Anthony W. Ferrante, JR., Aliki Kosteli
  • Patent number: 8569342
    Abstract: The present invention relates to essentially pure diastereomers of 4-aryloxy-3-hydroxypiperidines, including purified diastereomers of ifoxetine, methods of purifying said diastereomers, pharmaceutical compositions comprising said diastereomers and methods of treatment utilizing said pharmaceutical compositions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: October 29, 2013
    Assignee: Brentwood Equities, Ltd.
    Inventor: Balvinder Singh Rattan
  • Publication number: 20130237567
    Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.
    Type: Application
    Filed: April 25, 2013
    Publication date: September 12, 2013
    Applicants: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics Corporation
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20130202705
    Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.
    Type: Application
    Filed: May 9, 2011
    Publication date: August 8, 2013
    Applicant: Cima Labs Inc.
    Inventor: Ehab Hamed
  • Patent number: 8501782
    Abstract: The present application describes modulators of MIP-1? of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: August 6, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel S. Gardner, John V. Duncia, John Hynes, T.G. Murali Dhar, Percy H. Carter, Joseph B. Santella
  • Patent number: 8450345
    Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: May 28, 2013
    Assignees: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics Corporation
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Patent number: 8426445
    Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: April 23, 2013
    Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20130035353
    Abstract: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies.
    Type: Application
    Filed: July 31, 2012
    Publication date: February 7, 2013
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, GENETHON
    Inventor: Isabelle RICHARD
  • Patent number: 8367705
    Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: February 5, 2013
    Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Patent number: 8367835
    Abstract: Provided is a compound useful as a therapeutic drug for pain and inflammation caused by various pathological conditions such as neuropathic pain and rheumatoid arthritis. The compound of the formula (I) or a salt thereof [wherein R1 is a methyl group or a hydrogen atom, R2 represents a hydrogen atom, an alkyl group, an alkylcarbonyl group or an aryl carbonyl group, A represents a cycloalkyl group, a cycloalkenyl group, an aryl group or a heteroaryl group (each group may be substituted with a substituent selected from the group consisting of alkyl, alkenyl, cycloalkyl and halogen), n and m each represent an integer of 1, 2 or 3, and p represents an integer of 0, 1, 2 or 3].
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 5, 2013
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Yasunori Tsuzuki, Toshiya Morie, Takanori Nakamura, Isao Shimizu, Masanori Miyauchi
  • Publication number: 20130011344
    Abstract: It comprises the use of D-fagomine or derivatives thereof in the prevention and/or coadjuvant treatment of bacterial infections, as well as to pharmaceutical, veterinary, or food and feed, pet food compositions containing them.
    Type: Application
    Filed: March 24, 2011
    Publication date: January 10, 2013
    Applicant: BIOGLANE
    Inventors: Sergio Pumarola Segura, Josep Lluis Torres Simón
  • Publication number: 20120329781
    Abstract: The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 27, 2012
    Inventors: David James Dooley, Mark John Field, Richard Griffith Williams
  • Publication number: 20120283194
    Abstract: Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents for the ability to treat a cancer promoted by Hh pathway signaling. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
    Type: Application
    Filed: March 16, 2012
    Publication date: November 8, 2012
    Inventors: Scott X. Atwood, Anthony Oro
  • Publication number: 20120220632
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Application
    Filed: April 12, 2012
    Publication date: August 30, 2012
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: David Lockhart, Jeff Castelli
  • Patent number: 8211916
    Abstract: N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl] piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: July 3, 2012
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Publication number: 20120149733
    Abstract: The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and arthrosclerosis using the compound of the invention are disclosed.
    Type: Application
    Filed: June 15, 2011
    Publication date: June 14, 2012
    Inventors: Robert J. Cherney, John V. Duncia, Daniel S. Gardner, Joseph B. Santella, Zhongyu Wang
  • Publication number: 20120020954
    Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
    Type: Application
    Filed: March 28, 2010
    Publication date: January 26, 2012
    Inventors: Anat Achiron, Michael Gurevich
  • Patent number: 8071780
    Abstract: The present invention provides novel piperidine derivatives of formula (I), wherein R represents a substituted benzyl group, which are useful as inhibitors of glucosylceramide synthase (GCS). The compounds of the Invention are useful for treating various glycolipid storage diseases, such as Gaucher's disease, Sandhoff's disease, Tay-Schs disease, Fabry disease, and GM1 gangliosidosis; glycolipid accumulation disorders, such as Niemann-Pick disease, mucopolysaccharidoses, mucolipidosis type IV and ?-mannosidosis; various cancers that involve abnormal glycolipid synthesis; and various infectious diseases that involve cell surface glycolipids as receptors for the infectious organisms or for their toxins; as well as a variety of other disorders involving glycolipid synthesis, including neuronal disorders, inflammatory diseases, obesity, and the like.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: December 6, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventor: Michael Glen Orchard
  • Publication number: 20110294800
    Abstract: The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 1, 2011
    Applicant: The Trustees Of Columbia University in the City of New York
    Inventors: Yuli Xie, Shixian Deng, Donald W. Landry, Paul Harris, Antonella Maffei
  • Publication number: 20110263554
    Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.
    Type: Application
    Filed: November 6, 2009
    Publication date: October 27, 2011
    Applicant: WARF - Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
  • Publication number: 20110256150
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Application
    Filed: October 22, 2009
    Publication date: October 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
  • Patent number: 8022219
    Abstract: The present invention relates to the compound 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-[(4-(pentyloxy)phenyl)methyl]-, (2S,3S,4R,5S), or a pharmaceutically acceptable salt or prodrug thereof, which is useful as an inhibitor of glucosylceramide synthase. The compounds of the Invention are useful for treating various glycolipid storage diseases, such as Gaucher's disease, Sandhoff's disease, Tay-Sacs disease, Fabry disease, and GM1 gangliosidosis; glycolipid accumulation disorders, such as Niemann-Pick disease, mucopolysaccharidoses, mucolipidosis type IV and ?-mannosidosis; various cancers that involve abnormal glycolipid synthesis; and various infectious diseases that involve cell surface glycolipids as receptors for the infectious organisms or for their toxins; as well as a variety of other disorders involving glycolipid synthesis, including neuronal disorders, inflammatory diseases, obesity, and the like.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: September 20, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Michael Glen Orchard, David Ian Carter Scopes
  • Publication number: 20110190307
    Abstract: The present invention provides zebrafish based methods for the identification of compounds potentially useful in the treatment of motor neuron degenerative diseases (MNDDs), compounds identified by these methods and compositions, methods and medicaments for treating MNDDs.
    Type: Application
    Filed: June 25, 2009
    Publication date: August 4, 2011
    Inventors: Catherina G. Becker, Thomas Becker
  • Patent number: 7985760
    Abstract: Compounds of formula (I): wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: July 26, 2011
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Mezher Hussein Ali, Michael Glen Orchard
  • Publication number: 20110136868
    Abstract: Agents, which are both ceramide glucosyltransferase inhibitors and glucosidase inhibitors, may inhibit osteoclastogenesis and/or reduce osteoclast activation and, therefore, may be useful for osteolytic activity and bone loss in subjects with conditions, such as multiple myeloma.
    Type: Application
    Filed: July 30, 2010
    Publication date: June 9, 2011
    Inventors: Anastasios Karadimitris, Nikki Horwood, Amin Rahemtulla, Anne Dell, Terry Butters, Raymond Dwek
  • Publication number: 20110092541
    Abstract: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.
    Type: Application
    Filed: October 5, 2010
    Publication date: April 21, 2011
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Publication number: 20110091442
    Abstract: The present invention provides novel compositions as well as methods for preventing and/or treating lysosomal storage disorders. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.
    Type: Application
    Filed: October 5, 2010
    Publication date: April 21, 2011
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: Robert Boyd, Gary Lee, Philip Rybczynski
  • Publication number: 20110065754
    Abstract: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Filoviridae family using iminosugars, such as DNJ derivatives.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 17, 2011
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20110065752
    Abstract: Provided are novel iminosugars and methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Orthomyxoviridae family using iminosugars, such as DNJ derivatives.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 17, 2011
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20110065753
    Abstract: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 17, 2011
    Inventors: Urban Ramstedt, Brennan Kolse, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20110033519
    Abstract: The invention provides a device and a compound for the prevention and/or treatment of uterine fibroids in human patients, wherein the compound is dispensed from the device and is administered locally to the uterine tissue.
    Type: Application
    Filed: August 6, 2010
    Publication date: February 10, 2011
    Inventor: Madeline LEONG
  • Patent number: 7872010
    Abstract: Provided herein are compositions of a class of substituted diazabicycloalkane derivative compounds, which are useful as modulators of nicotinic acetylcholine receptors. The compounds are useful in treating conditions and disorders prevented by, or ameliorated by, nicotinic acetylcholine receptors.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: January 18, 2011
    Assignee: Abbott Laboratories
    Inventors: Jennifer M. Frost, Jianguo Ji, Tao Li, Diana L. Nersesian, Karin R. Tietje